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Garcinoic acid (GA or d-T3-13’COOH), is a natural vitamin E
metabolite that has preliminarily been identified as a modulator
of nuclear receptors involved in b-amyloid (Ab) metabolism
and progression of Alzheimer’s disease (AD). In this study, we
investigated GA’s effects on Ab oligomer formation and deposi-
tion. Specifically, we compared them with those of other vita-
min E analogs and the soy isoflavone genistein, a natural agonist
of peroxisome proliferator–activated receptor g (PPARg) that
has therapeutic potential for managing AD. GA significantly
reduced Ab aggregation and accumulation in mouse cortical
astrocytes. Similarly to genistein, GA up-regulated PPARg
expression and apolipoprotein E (ApoE) efflux in these cells
with an efficacy that was comparable with that of its metabolic
precursor d-tocotrienol and higher than those of a-tocopherol
metabolites. Unlike for genistein and the other vitamin E com-
pounds, the GA-induced restoration of ApoE efflux was not
affected by pharmacological inhibition of PPARg activity, and
specific activation of pregnane X receptor (PXR) was observed
together with ApoE and multidrug resistance protein 1 (MDR1)
membrane transporter up-regulation in both the mouse astro-
cytes and brain tissue. These effects of GA were associated with
reduced Ab deposition in the brain of TgCRND8 mice, a trans-
genic ADmodel. In conclusion, GA holds potential for prevent-
ing Ab oligomerization and deposition in the brain. The
mechanistic aspects of GA’s properties appear to be distinct
from those of other vitamin Emetabolites and of genistein.
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder characterized by the deposition of Ab (b-amy-
loid) plaques and tau neurofibrillary tangles, and by the
development of neuroinflammation and increased neuronal
cell death (1).
PPARg is a ligand-activated transcription factor implicated
in glucose and lipid metabolism with a known regulatory role
in AD pathogenesis, thus it has been recently investigated in a
therapeutic approach (2). Among its activity PPARg stimulate
the expression of a cholesterol transport protein apolipoprotein
E (ApoE), which is involved in the clearance of the soluble
forms of b-amyloid peptides (Ab). Such an important function
has been proposed to prevent Ab deposition in brain tissue and
neurotoxicity (3). As a consequence, ApoE metabolism and
function are recognized as both chemoprevention and thera-
peutic targets in AD (4). The possibility to tackle this target
with natural products has stimulated a wealth of studies over
the last decades (reviewed in Ref. 5). For example, the soy isofla-
vone genistein has demonstrated great potential to cure cogni-
tion and memory symptoms in a genetically-determined mu-
rine model of AD (6). Genistein was identified to produce a
remarkable activity on PPARg-dependent stimulation of ApoE
expression (7).
Also a-tocopherol (a-TOH, Fig. 1), the most abundant
form of vitamin E and the main fat-soluble antioxidant of
human tissues (8), has long been considered a natural neu-
roprotectant and regulatory molecule of brain immune-
inflammatory cells, i.e. glial that include astrocytes, oligo-
dendrocytes, and microglia (9–11). Similarly to genistein,
a-TOH is reported to influence the transcriptional activity
of PPARg (12, 13), as well as of PXR (14, 15), which may
explain the reported influence of this vitamin on ApoE me-
tabolism of the brain and other tissues (16, 17). Again,
a-TOH was previously described to reduce Ab levels and
amyloid deposition in Tg2576 transgenic mice (18).
Preliminary studies by some of us described a potent
effect of long-chain metabolites (LCMs) of vitamin E (Fig. 1)
as inducers of PPARg expression in human hepatocytes
(19). These LCMs included the CYP450-derived metabolites
of a-TOH, e.g. a-13’OH and a-13’COOH, and garcinoic
acid (GA or d-13’COOH) (20), a natural analog of LCMs
deriving from delta-tocotrienol (d-T3) structure (Fig. 1).
Recent evidence in literature also suggested a function of
these LCMs (15), and especially of GA (21), as PXR agonists.
This nuclear receptor is a central hub of xenobiotic metabo-
lism (22) and its transcriptional role is proposed to control
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the CYP450-mediated metabolism of vitamin E, possibly by
CYP4F2 and CYP3A4 isoenzyme regulation (14, 23, 24).
Several studies also suggested a role of PXR in Ab clearance
through P-glycoprotein (P-GP or MDR1) dependent trans-
port at the blood-brain barrier (25–27).
These effects of GA and other LCMs on nuclear receptor
activity, along with the capability of vitamin E to cross the
blood-brain barrier (28), are features in common with genis-
tein, which may hold potential to prevent Ab deposition and
neurotoxicity. Therefore, in this study GA and a series of vita-
min E analogs, were investigated for their effect on Ab aggre-
gation and metabolism in mouse cortical astrocytes. The
properties of GA were also investigated in a transgenic mouse
model that spontaneously accumulate amyloid plaques.
Results
In vitro studies
Cell-free assay of Ab aggregation—The ThT fluorescence
assay was utilized to investigate whether GA directly influences
Ab aggregation in cell-free experiments (Fig. 2A). Ab42 fibrils
formation showed a sigmoidal kinetics that reached a maxi-
mum of fluorescence after 48 h of incubation. In the presence
of GA or GE, Ab aggregation peaked at 24 h then decreasing
progressively up to 72 h. TEM images (Fig. 2B) showed that GA
treatment causes the formation of short protofibrils after 24 h,
followed by the presence of amorphous ThT negative material
at 72 h. GE also inhibited the development of mature fibrils af-
ter 72 h.
Ab aggregation and metabolism in mouse astrocytes—First,
acute toxicity in mouse astrocytes was excluded for all the test
compounds (GE, a-TOH, a-LCMs, GA, and d-T3) investigated
either separate (Fig. S1A and Table S1) or combined with Ab
treatment (Fig. S1B, Table S1). In these tests cell viability was
assessed by trypan blue dye exclusion (Fig. S1, A and B), MTT
and CCK-8 assay (Table S1). Immunolocalization of Ab1-42
aggregates demonstrated that the pre-treatment with GA
and GE reduces the number and dimension of Ab oligomers
that interact with the plasmalemma of murine astrocytes
(Fig. 2C).
ApoE efflux and nuclear receptor function—As a major find-
ing in this study, Abwas found to significantly reduce the capa-
bility of astrocytes to release ApoE in the extracellular medium
(Fig. 2D) and this negative effect of Ab was completely pre-
vented by the pre-treatment with GA as well as of genistein
(Fig. 2D) anda-13’OH, but not a-13’COOH (Fig. S2). In the ab-
sence of Ab, GA stimulated ApoE efflux (Fig. 2D), whereas a
trend toward a decreased efflux was observed in the case of
a-13’COOH and a-13’OH (Fig. S2).
The PPARg activity inhibitor T0070907 was utilized to verify
the functional contribution of this nuclear receptor in the
response of ApoE efflux to GA and other compounds, a role
that has already been described for genistein (2, 16). The treat-
ment with a-13’COOH was excluded from this experiment
because of its negative effect on ApoE efflux after Ab treatment
(Fig. 2D). T0070907 hampered part of the stimulation effect
that GE and a-13’OH produced on ApoE efflux. This effect
was not observed on the efflux response to GA that rather
increased in the presence of this PPARg inhibitor (Fig. 2D).
This finding reveals a PPARg-independent stimulation
effect of GA on ApoE efflux in mouse cortical astrocytes
exposed to Ab. GA increased PPARg protein expression
(Fig. 2E) restoring its levels that, analogously to ApoE efflux
(Fig. 2D), were decreased after Ab treatment. With the
exception of a-13’OH, pretreatments with all the other vita-
min E molecules restored the expression of this NR with re-
markable increases observed in the case of a-13’COOH and
d-T3 (Fig. 2E and Fig. S2E).
Because the activity of GA appears to be at least in part inde-
pendent from PPARg activity, another molecular target of this
plant metabolite that may sustain ApoE transport and Ab
clearance through P-GP orMDR1 up-regulation (25–27, 29), is
PXR (15, 21). GA was confirmed to be a potent activator of
PXR protein expression also in mouse astrocytes (Fig. 2, F and
H) and, together with d-T3, it significantly stimulates CYP4F2
(Fig. 2G) and MDR1 (Fig. 2I) expression. These are PXR re-
porter genes not affected by the PPARg-activating compound
genistein. Similarly to ApoE and PPARg, PXR expression was
also reduced in mouse astrocytes by the treatment with Ab,
and GA pre-treatment restored the levels of this nuclear recep-
tor (Fig. 2H).
GA availability, modulation of target genes, and ab
metabolism in mouse brain
Bioavailability and target engagement of GAwas investigated
in mouse brain. In C57Bl/6 mice administered with a single
bolus of GA, the concentration-dependent response of PPARg,
PXR, and ApoE expression was demonstrated by immunoblot
(Fig. 3, A–C), and PXR up-regulation was also confirmed by
IHC with some astrocytes showing cytoplasmic localization of
Figure 1. Structures of test compounds. GE, a-TOH, and its LCM a-13’ OH,
a-13’COOH, d-T3, and its metabolite analog garcinoic acid (dT3-13’ COOH).
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Figure 2. Ab aggregation andmetabolism in mouse cortical astrocytes treated with genistein or garcinoic acid. A, ThT fluorescent test was utilized to
assess cross-b-sheet structure of Ab(1–42) during formation of amyloid aggregates in cell-free experiments. Fluorescence was investigated for 72 h in the ab-
sence or in the presence of GE (5mM) or GA (25mM). B, Structural aspects of Ab aggregation were investigated by transmission EM; scale bars, 500mM. Ab(1–42)
aggregates on the plasma membrane of mouse astrocytes pre-treated with test molecules were assessed by immunofluorescence. Scale bars, 11 mM. D–I, im-
munoblot of extracellular ApoE and cellular levels of PPARg, PXR, CYP4F2, andMDR1. Determinations were carried out inmouse cortical astrocytes pre-treated
with GE (5mM), GA (25 mM) or d-T3 (2.5 mM), and then exposed to Ab. In some experiments, the effect of the PPARg activity inhibitor T0070907 was also investi-
gated (D). Further details on cell treatments and determinations are reported under :Experimental procedures.” #, p, 0.05 versus Ctr test; *, p, 0.05 versus Ab
test.
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the receptor at the higher dose of GA investigated in this study
(25mg) (Fig. 3D).
Bioavailability of GA in Tg mice was assessed in plasma and
brain samples by GC-MS analysis (Fig. 3, F andG). Semiquanti-
tative results of brain samples were compatible with GA con-
centrations in parietal cortex (PC) and hippocampus (H) of Tg
mice treated with GA (Tg 1 GA) between 0.8 and 10.3 ppm
(ng/mg of proteins) (Fig. 3G, right panel).
IHC data demonstrated that GA prevents the formation
and reduces the size and morphological complexity of Ab
plaques throughout the brain of Tg mice, namely the entire
cortical mantle and subcortical regions (Fig. 4, A and B).
Quantitative analysis of the pE3 -Ab plaque number in 14-
15-month–old Tg mice demonstrated a significant reduc-
tion in the number of all size amyloid plaques by GA treat-
ment (inset to Fig. 4A). These findings were also confirmed
by Congo Red staining of brain samples (Fig. 4, C and D); in
these experiments the decreased accumulation of Ab depos-
its was particularly evident in oldest Tg mice (14 to 15-
month–old) that accumulate a much severe form of Ab
deposits (upper panels) compared with youngest (5-month–
old Tg mice, lower panel). Representative control images of
Congo Red histology are shown in Fig. S5.
ApoE protein expression assessed by immunoblot (Fig. S3B)
significantly increased in the hippocampus of Tg mice treated
with GA. Similarly, GA stimulated MDR1 expression in the
hippocampus (Fig. S3, C and D) and parietal cortex (not
shown).
Immunohistochemistry data did not show a marked effect of
GA treatment on PXR expression in brain tissue of Tg mice
(Fig. S4A). PXR is widely present in the brain tissue Tg mice,
but in lower amount compared with the liver (Fig. S4, A versus
B). In hepatocytes of Tg mice treated with GA, slightly
increased levels of PXR were observed (Fig. S4B). According
to Ref. 30, PXR is highly expressed in the gut and GA treat-
ment stimulates its expression, mainly in enterocyte crypts
(Fig. S4C).
Discussion
In this study, GA, the natural analog of d-T3-13’COOH, has
been evaluated for the first time in an in vitro model of Ab
aggregation and cytotoxicity (31), and in vivo in TgCRND8
mice, a transgenic model of Ab deposition (32). Ab aggrega-
tion, and the gene response associated with the cellular metab-
olism of this peptide, have been evaluated.
GA showed a good safety profile (absence of major cytotoxic
effects at micromole levels) and was the most efficient between
the vitamin E analog investigated in this study to decrease Ab
accumulation in mouse astrocytes. Mechanistic investigation
indicates that similarly to genistein, GA interferes with the
aggregation properties of Ab and it is effective in stimulating
ApoE efflux and MDR1 transporter expression, which are im-
portant to sustain the cellular clearance of the peptide. In fact,
thereby preventing its interaction with the plasmalemma (Fig.
2), which are important prerequisites to lessen its intrinsic cy-
totoxicity (31). This detoxification response to GA could be
explained by the marked up-regulation of PPARg and PXR nu-
clear receptors, the expression of which is impaired by the
treatment with Ab. The fact that GA efficiently prevented the
defect of these receptors, restoring MDR1 levels and the efflux
of ApoE, may thus suggest a chemoprotection function for this
natural compound.
The PPARg activation response of GA confirms and extends
the preliminarily findings obtained in human hepatocytes (19),
indicating similarities with the therapeutic mechanism of ge-
nistein. Our data demonstrate that this soy isoflavone is a
potent agonist of the PPARg-induced efflux of ApoE in Ab-
treated astrocytes, possibly more potent than GA. This PPARg-
mediated response to genistein was already indicated to explain
its therapeutic potential in genetically-determined AD mice
(6). Moreover, it may have effects on both the phagocytosis of
Ab by microglial cells (3) and its clearance by the activation of
brain target genes involved in the reverse cholesterol transport,
such as ApoE and ABCA1 (33).
Pharmacological inhibition experiments, however, suggested
that the ApoE efflux response to GA, but not to GE or other
vitamin E molecules, such as d-T3 and a-13’OH, is at least in
part independent from PPARg activity. Nuclear receptors alter-
native to PPARg, that may produce similar or evenmore potent
effects on ApoE transcription and efflux, include PXR. In fact,
this receptor is reported to influence ApoE transport and Ab
clearance through P-glycoprotein (P-GP or MDR1) up-regula-
tion (25–27, 29).
Our findings demonstrate for the first time an agonistic
effect of GA on brain PXR. Upon treatment, PXR increased its
own expression and that of the reporter geneMDR1, a response
that was already described for LCMs and dT3 in intestinal cells
(15). GA up-regulated MDR1 expression not only in mouse
astrocytes, but also in vivo in the brain of WT and Tg mice.
Moreover, we demonstrate that the treatment with GA, but not
genistein, stimulates the expression of another PXR-regulated
gene with proposed activity in thev-oxidation of vitamin E side
chain, e.g.CYP4F2 (34). These results are in line with recent ex-
perimental evidence that demonstrates a selective PXR agonist
activity of GA, which is specific for this vitamin E metabolite
(21). Consistent biochemical and functional evidence support
these findings including the co-crystallization of GA with the
LBD of PXR nuclear receptor, thermodynamic data, target
engagement and the transcriptional response of different tis-
sues that include gut and liver tissues in which PXR is abun-
dantly expressed and important for its detoxification function
(21). The response of intestinal and hepatic PXR to GA treat-
ment is confirmed in the present study and it is described for
Figure 3. Brain target engagement and bioavailability of GA. Immunoblot was utilized to assess PPARg (A), PXR (B), and ApoE (C) expression in brain of
C57Bl/6 mice treated with different concentrations of GA. The brain PXR expression of these animals was also verified by IHC analysis (D). GC-MS was utilized
to assess the availability of GA (mass spectrum and ion chromatogram atm/z 512.4 for GA detection are shown in E to plasma (F) and brain tissue (G) of WT, Tg
and Tg1GAmice. Brain samples were collected in three different areas: parietal cortex (PC), hippocampus (H), and frontal cortex (FC). Data were as mean6 S.
D. of three experiments. *, p, 0.05 versus Ctr test; **, p, 0.01 versus Ctr test.
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first time to extend to some areas of the brain (Fig. 3), which
may help to explain the improved Ab deposition phenotype of
TgCRND8mice (Fig. 4).
However, the absence of a consensus sequence in the pro-
moter region of the APOE gene specific for this nuclear recep-
tor and its dimeric complex with RXR (assessed in Refs. 35 and
36), may lead to exclude a direct transcriptional effect of PXR
on APOE gene. Considering indirect effects, PXR-dependent
genes involved in this response may include ABCA1 and/or
MDR1 gene regulation with important role in preventing Ab
deposition (25–27, 29). At the same time, target engagement
experiments in WT mice (Fig. 3) demonstrate that PXR and
PPARg are both activated with a similar concentration-de-
pendent response to GA in the brain. This may lead to hypothe-
size converging mechanisms of transcriptional regulation by
NR on APOE and other genes with key role in Ab metabolism
that are worth investigating further.
Cellular experiments in study further emphasizes the con-
cept that different vitamin E derivatives have different gene reg-
ulatory functions (37, 38). Compared with d-T3, the use of GA
may directly modulate ApoE activity avoiding the need for an
efficient bioavailability and metabolism of d-T3 to form d-T3-
13’COOH in the brain. Important enough, GA shows much
lower cytotoxicity compared with d-T3, thus allowing treat-
ments with much higher doses; furthermore, the more hydro-
philic properties of GA may favor compound permeability
through the blood-brain barrier. The fact that GA is available
to the mouse brain and, along with PPARg, it up-regulates PXR
expression of this tissue, suggests other pharmacological appli-
cations, including anxiety-like behavior and recognition mem-
ory (39), and blood barrier functionmodulation (40) that are all
PXR-dependent processes. Other therapeutic effects of GA
could be anticipated in lipid and metabolic disorders associated
with higher demand of ApoE activity or unfavorable APOE
haplotypes (41, 42).
In conclusion, in the present study GA was demonstrated to
have compound-specific effects useful to prevent Ab accumu-
lation in the mouse brain, being capable at the same time of 1)
interfering with Ab polymerization, 2) stimulating the ApoE
and MDR1 detoxification system of mouse cortical astrocytes
and the brain tissue, and 3) reducing Ab deposition in the brain
of TgCRND8 mice, an animal model of AD. Pharmacological
and target engagement data suggest that the PXR and PPARg
agonist properties of GA could help to explain a better cellular
clearance of Ab by the increased expression and activity of
ApoE and MDR1 transporter. Altogether these findings indi-
cate that GA holds potential in chemoprevention and therapy
of AD that is worth of further investigation.
Figure 4. Effect of GA on Ab aggregate formation in the brain of TgCRND8mice. IHC analysis of pyroglutamate-3 Ab (pE3 -Ab) (A and B) and Congo Red
histology (C and D) of entire hemibrain sections were performed in TgCRND8mice after 10-day oral administration of GA (200 mg/kg; Tg1GA group) or vehi-
cle (olive oil; Tg group). Control images of Congo Red staining are reported under Fig. S5. Other details on these animal experiments are reported under “Ex-
perimental Procedures.” Insert to panel A: bar chart of Ab plaque number in the entire hemisphere of 14-15-month–old Tg mice; plaque number was
determined automatically on digitized images using the CellSens Dimension software (Olympus, Germany); **, p, 0.005 and *, p, 0.05 versus respective area
size of untreated Tg.
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Thioflavin-T (ThT) and transmission EM of Ab1-42 aggregates
ThT was utilized as a fluorescent probe to the specifically
bound cross-b-sheet structure of amyloid. Formation of Ab(1-
42) aggregates was investigated for different times between 0
and 72 h in the absence or presence of GE (5 mM) or GA (25
mM). The aggregates were diluted to 15 mM monomeric peptide
concentration with 20mM phosphate buffer, pH 7.4, at 25 °C,
and then were supplemented with ThT (20 mM final concentra-
tion). The samples were transferred into 96-well–plate, and
ThT fluorescence (450 excitation/482 emission) was recorded
using a Biotek Synergy 1H plate reader. For TEM analysis, 5-ml
aliquots of Ab(1-42) aggregated were withdrawn at 24 and 72
h, and loaded onto a formvar/carbon-coated 400 mesh nickel
grids (Agar Scientific, Stansted, UK) and negatively stained
with 2.0% (w/v) uranyl acetate (Sigma-Aldrich). The grid was
air-dried and examined using a JEM1010 transmission electron
microscope at 80 kV excitation voltage.
Cell culture conditions and treatments
Mouse cortical astrocytes were cultured from dissected
cerebral cortices of neonatal C57BL/6J mice. 3 to 4 brain
samples were utilized to seed the cell suspension in a 150-
cm2 culture flask (NUNC, Roskilde, Denmark). The cells
were maintained at 37 °C in a humidified incubator with 5%
CO2 atmosphere, utilizing Dulbecco’s modified Eagle’s me-
dium/F-12 culture medium (1% L-glutamine) supplemented
with 10% fetal bovine serum (Thermo Fisher Scientific),
62.5 mg/ml of penicillin and 100 mg/ml of streptomycin
(Sigma-Aldrich). At confluence, the astrocytes were seeded
in 25-cm2 culture flasks at a density of 53 105 cells per flask
and were maintained in culture for 5 to 6 days (80–90% con-
fluence) before utilization. Treatments were carried out to
assess GA and other test compounds (Fig. 1) in chemopre-
vention mode with the following protocol:
Pre-treatment step—The cells were exposed for 24 h to vehi-
cle (0.001% (v/v) ethanol) or test compounds: genistein (5 mM;
Sigma-Aldrich), a-TOH, a-13’-OH, and a-13’-COOH LCMs,
GA (25 mM final concentration each; prepared according to
Refs. 21 and 43), and d-T3 (2.5mM, Cayman).
Treatment step—After washing, the cells were exposed for
24 h to 5 mM Ab(1-42) (GenScript) in fresh medium. These
conditions of treatment (time of exposure and concentra-
tion of Ab) were selected to maintain the reduction of cell
viability , 20% and thus to perform chemoprevention
experiments with a sufficient number of viable cells (Table
S1). Culture media were collected after pre-treatment and
treatment steps for ApoE determination. In some experi-
ments, the pre-treatment step was performed in the pres-
ence of the PPARg activity inhibitor T0070907 (10 nM in
EtOH, Sigma Aldrich) (44).
Cell viability
Trypan blue exclusion assay—After treatment, the cells were
washed in PBS and then detached with Trypsin-EDTA for col-
lection by centrifugation and resuspension in 2 ml of culture
medium containing 0.2% (w/v) trypan blue. Trypan blue-posi-
tive cells and total cells were counted by a single operator under
a light microscope in four (1 3 1 mm) fields of a Neubauer
chamber.
MTT assay—The MTT reagent (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich) was
added to astrocytes seeded in 96-well–plates (23 103 cell/well)
at 0.5 mg/ml final concentration. After a 3-h incubation step
(37 °C), formazan crystals formed by the reducing activity of
mitochondrial dehydrogenases on MTT were dissolved with
100 ml of solubilization solution and absorbance was measured
at 570 nm in a microplate reader. Nonviable cells are unable to
reduce theMTTdye.
CCK-8 assay—10 ml of CCK-8 reagent (Cell Counting Kit-8,
Dojindo Molecular Technologies, Inc.) was added to each well
seeded with 2.53 103 astrocytes. After incubation (2 h), the ab-
sorbance was recorded at 450 nm wavelength using a micro-
plate reader (Becton Dickinson).
Immunofluorescence assay
Subconfluent astrocytes grown on glass coverslips were pre-
treated with GE (5 mM) or GA (25 mM) for 24 h and then incu-
bated with Ab 5 mM for the following 24 h. The oligomers and
the cell membrane were stainedwith rabbit anti-Ab(1-42) poly-
clonal antibody followed by the Alexa Fluor 568-conjugated
secondary antibodies (red channel) and the Alexa 488-toxin
cholera (staining GM1membrane; green channel), respectively.
Cell fluorescence was imaged using a confocal Leica TCS SP5
scanning microscope (Leica, Mannheim, Germany) equipped
with a HeNe/Ar laser source for fluorescence measurements.
The observations were performed using a Leica Plan 7 Apo 3
63 oil immersion objective. FRET analysis was performed by
adopting the FRET sensitized emission method, as previously
reported (45).
Animal experiments
Blood and brain tissue availability of oral GAwas preliminar-
ily investigated in 8-week–old male C57Bl/6 mice (18–22 g;
Charles River Laboratories International, Inc., Wilmington,
MA, USA). All animal procedures were approved by the Ani-
mal Ethics Committee of the University of Perugia and were
performed in accordance with the Italian code for care. Mice
were randomly assigned to receive an oral dose of 5, 10, or 25
mg of GA (n = 3/dose cohort) or vehicle (olive oil, n = 3). At the
end of treatment, the animals were anesthetized and sacrificed
according to institutional guidelines, and blood and brain tissue
samples were collected for histology and biochemistry assays.
Grouping of animals and quantifications were blinded for the
responsible researchers throughout the study.
To investigate the effect of GA on Aë deposits, 5-month
and 14-15-month–old TgCRND8 (Tg) mice (n = 3) were
used. Five-month–old WT (WT) (n = 2) mice were also uti-
lized as controls. Tg mice harboring a double-mutant gene of
APP695 (32) and WT control littermates were used in ac-
cordance with the principles of the Basel Declaration and the
Working document on genetically altered animals - CORRI-
GENDUM of 24 January 2013, of the National Competent
Garcinoic acid reduces b-amyloid deposition in the mouse brain





















Authorities for the implementation of Directive 2010/63/EU
on the protection of animals used for scientific purposes.
According to the Italian Regulation (D.Lvo 26/2014), the pro-
tocol was revised and approved by the Animal Welfare Body
of the University of Florence and licensed by the Italian Com-
petent Authority (Italian Ministry of Health, license number
71/2017-PR). Animals were housed in macrolon cages with
food and water ad libitum and maintained on a 12-h light/
dark cycle at 23 °C. All efforts were made to minimize the
number of animals used and their suffering.
Tgmice were orally administered with GA (200mg/kg; Tg1
GA group) or vehicle (olive oil; Tg group) for 10 days. The ani-
mals were weighed once a day, and the bodyweight recorded
and the dose to be orally administered was recalculated accord-
ing to the body weight. After completing the treatments, blood
samples were collected into EDTA-coated tubes, then the ani-
mals were sacrificed by cervical dislocation and brains were
quickly dissected on dry ice; frontal and parietal cortex and hip-
pocampal samples were stored at 280 °C until use. Liver and
gut specimens were also collected and fixed, as well as hemi-
brain samples, with 4% ice-cold paraformaldehyde in 0.1 M
PBS, pH 7.2, for 24 h at 4 °C, and histochemical and immuno-
histochemical analyses were performed on 4 mM paraffin-em-
bedded sections.
GC-MS analysis of GA
Approximately 33 mg of homogenized brain tissues (parietal
cortex, frontal cortex, and hippocampus) and 150 ml of plasma
were utilized to determine GA availability in TgCRND8 mice.
Samples were mixed with 1ml of sodium acetate buffer, pH 5.0,
and incubated overnight at 37 °C with 40 ml of an enzymatic
mixture containing b-glucuronidase (100,000 units/ml) and
Helix pomatia type H2 sulfatase (7500 units/ml) (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany). Salting out
extraction of hydrolyzed samples was carried out by QuECh-
ERS (Phenomenex, Italy) utilizing acetonitrile, anhydrous mag-
nesium (4 g), sodium chloride and sodium citrate (1 g each), so-
dium citrate dibasic sesquihydrate (0.5 g), followed by a
dispersive solid-phase cleanup stepwith anhydrousmagnesium
(900 mg), and 150 mg each of PSA and C18 (Phenomenex,
Italy). Further purification of the extracted samples was carried
by silica gel TLC. The concentrated extracts were methylated
for 30 min in 3 N methanolic HCl and silylation was carried out
utilizing N,O-bis(trimethylsilyl)trifluoroacetamide 1 1% tri-
methylsilyl chloride/pyridine at 65 and 60 °C, respectively.
Samples were analyzed using an Agilent Technologies GC-MA
work station consisting of a MSD 5975C Triple Axis Detector
coupled with a gas chromatograph (GC 7890A) equipped with
an VF-5 ms capillary column (15 m3 0.15 mm inner diameter,
0.15 mM film thickness). GA analysis was calibrated utilizing an
authentic standard prepared according to Refs. 21 and 43.
Immunoblot of astrocytes and brain tissue proteins
To extract astrocytes proteins, the cells were incubated for
40 min at 4 °C in lysis buffer (Cell Signaling Technologies) sup-
plemented with protease and phosphatase inhibitor mixture
(Pierce, Thermo Fisher Scientific), and fresh 1mM phenylmeth-
ylsulfonyl fluoride (Sigma-Aldrich, MO, USA). After incuba-
tion, the samples were centrifuged (14,000 rpm for 30 min at 4 °
C), and the supernatants and pellets were collected for immu-
noblot analysis. Cell culture media of astrocytes were also col-
lected and processed for protein extraction to measure ApoE
efflux.
Brain homogenization for protein extraction (;200 mg of
tissue) was carried out in protein extraction buffer (Trizma
(Tris base), 10 mM Nonidet P-40, KCl 154 mM, and fresh phen-
ylmethylsulfonyl fluoride, pH 7.6) with freshly added protease
inhibitors (DTT, leupeptin, and aprotinin) using mortar-pestle
and sonication methods. After centrifugation (27,000 3 g, 20
min), the supernatant was collected for immunoblot. Mem-
brane proteins were separated utilizing a Cell Fractionation Kit
(#9038, Cell Signaling Technology Inc.) according to manufac-
turer's instructions. Total proteins of cell lysates or brain
homogenates were quantified by BCA assay (Thermo Fisher
Scientific).
Immunoblot of ApoE, was performed on both the cell culture
media and cellular extracts by protein separation on 10% SDS-
PAGE and subsequent electroblotting to a polyvinylidene diflu-
oridemembrane. After blocking with 5% nonfat milk, themem-
brane was incubated with an anti-Lipoprotein E antibody
(ab83115; Abcam). For the other antigens, proteins (20 mg)
were resolved by 12% SDS-PAGE and transferred to a nitrocel-
lulose membrane (Thermo Fisher Scientific). After blocking
with 5% nonfat milk, the blots were incubated with primary
antibodies (anti-ApoE (1:1000, Abcam), anti-CYP4F2 (1:500,
Santa Cruz Biotechnology), anti-PPAR-g (1:1000, Cell Signal-
ing Technologies), anti-PXR (1:200 dilution; Santa Cruz Bio-
technology, Inc.), anti-MDR1 (1:1000, Cell Signaling Technolo-
gies) anti-a-tubulin control (Abcam-ab4074), anti-GAPDH
(1:1000, Cell Signalling Technologies), anti-b-actin (1:1000,
Cell Signalling Technologies), and anti-b-catenin (1:2000, BD
Transduction LaboratoriesTM)), and then with an horseradish
peroxidase-conjugated secondary antibody (1:2000, Cell Signal-
ing Technologies). Total protein normalization was performed
using Ponceau S staining. Band detection was carried out by
ECL-plus solution (Pierce, Thermo Fisher Scientific) according
to the manufacturer’s instructions. Images of blotted mem-
branes stained with Ponceau and films were captured by
“Imagequant LAS4000” (GE-Healthcare Bio-Sciences) and ana-
lyzed with “Image J” software.
IHC and Congo Red histochemistry
Brain, liver, and gut tissue specimens were formalin-fixed
and paraffin-embedded. Four micrometer sections were
mounted on polarized glass slides. One slide from each case
was stained with hematoxylin and eosin (Sigma-Aldrich). Im-
munohistochemical analysis of PXR (polyclonal IgG, dilution
1:200; Abcam) was performed using Bond III automated slide
preparation system and Polymer Refine antibody detection sys-
tem (Vision BioSystems, Buffalo Grove, IL, USA). Diaminoben-
zidine was used as chromogen. The sections were then counter-
stained with hematoxylin and mounted with Digital Picture
Exchange.
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For Cong Red staining 8-mm sections were cut from forma-
lin-fixed and paraffin-embedded mouse brain tissue and
mounted on glass slides. Staining was performed using Congo
Red Stain Kit (DAKO) on an automated slide preparation
Dako’s Artisan Staining system. Sections were then counter-
stained with hematoxylin and mounted according to manufac-
turer’s instruction. Samples were evaluated using both standard
and polarized light microscopy. Ab plaque burden was ana-
lyzed in brain slices stained with the anti-N3pE antibody (1:200
diluted, IBL international, Hamburg, Germany) (46), which
recognizes the pyroglutamate-3 Ab (pE3 -Ab) and was
digitized and acquired with an Olympus BX63 microscope
equipped with the CellSens Dimension software (Olympus,
Germany). The number of pE3-Ab plaques of different sizes
was determined in 14-15-month–old Tg mice staining 1 entire
hemisphere section of eachmouse brain.
Statistics
Data were as mean 6 S.D. and statistical significance was
evaluated by one-way analysis of variance followed by Bonfer-
roni post hoc test, utilizing the statistics package of GraphPad
Prism version 5.0 (San Diego, CA, USA); Student’s t test was
used to compare differences between pE3-Ab plaque data. A
probability of error,0.05 was considered significant.
Data availability
All data are contained within the article.
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